990 Federal Register / Vol. 75, No. 4 / Thursday, January 7, 2010 / Notices 

Camptothecins are effective 

Topoisomerase I (Top1) inhibitors, and 

two derivatives (Topotecan® and 

Camptosar®) are currently approved for 

treatment of ovarian and colorectal 

cancer. Camptothecins damage DNA by 

trapping covalent complexes between 

the Top1 catalytic tyrosine and the 3′- 

end of the broken DNA. Tdp1 repairs 

Top1–DNA covalent complexes by 

hydrolyzing the tyrosyl-DNA bond. 

Thus, the presence and activity of Tdp1 

can reduce the effectiveness of 

camptothecins as anticancer agents. In 

addition, Tpd1 repairs free-radicalmediated DNA breaks. 

Inhibition of Tpd1 using diamidine or 

its derivatives. may reduce repair of 

DNA breaks and increase the rate of 

apoptosis in cancer cells. In addition. 

diamidine derivatives have the potential 

to enhance the anti-neoplastic activity 

of Top1 inhibitors, by reducing repair of 

Top1–DNA lesions through inhibition of 

Tdp1. 

Development Status: Pre-clinical 

stage. 

Inventors: Yves G. Pommier and 

Christoph Marchand (NCI). 

Publications 

1. Z Liao et al. Inhibition of human tyrosylDNA phosphodiesterase by aminoglycoside 

antibiotics and ribosome inhibitors. Mol 

Pharmacol. 2006 Jul:70(1):366–372. 

2. Y Pommier. Camptothecins and 

topoisomerase I: a foot in the door. Targeting 

the genome beyond topoisomerase I with 

camptothecins and novel anticancer drugs: 

importance of DNA replication, repair and 

cell cycle checkpoints. Curr Med Chem 

Anticancer Agents. 2004 Sep; 4(5):429–434. 

Review. 

3. Y Pommier et al. Repair of and 

checkpoint response to topoisomerase I 

mediated DNA damage. Mutat Res. 2003 Nov 

27;532(1–2):173–203. Review. 

Patent Status: U.S. Patent Application 

No. 12/225,672 filed 26 Sep 2008 (HHS 

Reference No. E–165–2006/0–US–04). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Betty Tong, PhD; 

301–594–6565; tongb@mail.nih.gov. 

Collaborative Research Opportunity: 

The Laboratory of Molecular 

Pharmacology is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize Tdp1 inhibitors for the 

treatment of cancers. Please contact 

John D. Hewes, PhD at 301–435–3121 or 

hewesj@mail.nih.gov for more 

information. 

Dated: December 23, 2009. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E9–31284 Filed 1–6–10; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

HHS Intent To Publish Grant and 

Contract Solicitations for Comparative 

Effectiveness Research (CER) Projects 

With Funds Allocated to the Office of 

the Secretary From the American 

Recovery and Reinvestment Act 

(ARRA) 

AGENCY: Agency for Healthcare Research 

and Quality (AHRQ), HHS. 

ACTION: Notice of intent. 

SUMMARY: The Department of Health and 

Human Services announces its intention 

to support new CER projects with funds 

allocated by the American Recovery and 

Reinvestment Act (ARRA). The ARRA 

appropriated $400 million to the Office 

of the Secretary for support of CER. 

AHRQ has been designated point of 

contact for management of these funds. 

Prioritization of the OS ARRA CER 

allocation was determined by several 

factors: public input, the Comparative 

Effectiveness Research-Coordination 

Implementation Team, the Federal 

Coordinating Council for Comparative 

Effectiveness Research (FCC), and the 

Institute of Medicine Report on CER. OS 

ARRA CER projects will focus, initially, 

on either (1) one of the 14 priority 

conditions established by the Secretary 

of the Department of Health and Human 

Services under Section 1013 of the 

Medicare Prescription Drug, 

Improvement, and Modernization Act of 

2003, (2) 100 Institute of Medicine topic 

recommendations, or (3) topics that fall 

into one of the AHRQ identified 

evidence gaps or are identified in the 

FCC report. An additional integral focus 

for these OS ARRA CER funds are the 

priority populations, which include low 

income groups; minority groups; 

women; children; the elderly; and 

individuals with special health care 

needs, including individuals with 

disabilities and individuals who need 

chronic care or end-of-life health care. 

The CER solicitations will come from a 

diverse set of divisions and agencies 

across the Department of Health and 

Human Services. 

DATES: HHS anticipates grant and 

contract solicitations to be published 

over the next several months. 

ADDRESSES: The future CER funding 

opportunity announcements will be 

published in the NIH Guide: http:// 

grants.nih.gov/grants/guide/index.html 

and on Grants.gov.: http:// 

www.grants.gov/. Contract solicitations 

can be found on the Federal Business 

Opportunity site at https://www.fbo.gov/ 

index?cck=1&au=&ck=. 

FOR FURTHER INFORMATION CONTACT: 

Until the solicitations are published, 

AHRQ cannot provide information on 

their contents. 

Direct any general comments 

regarding the OS ARRA CER program 

to: Kathleen Kendrick, Deputy Director, 

Office of the Director, Agency for 

Healthcare Research and Quality, 540 

Gaither Road, Rockville, MD 20850, 

Telephone: 301–427–1200, e-mail 

address: ARRA 

Support@AHRQ.HHS.gov. 

SUPPLEMENTARY INFORMATION: 

Background 

The American Recovery and 

Reinvestment Act (ARRA) provided $1.1 

billion for comparative effectiveness 

research (CER). The Act allocated $300 

million to the Agency for Healthcare 

Research and Quality (AHRQ), $400 

million to the National Institutes of 

Health (NIH), and $400 million to the 

Office of the Secretary (OS) of the 

Department of Health and Human 

Services (HHS). These funds are 

dedicated specifically towards CER and 

must be obligated by the end of fiscal 

year 2010. 

Comparative Effectiveness Research 

Initiative Description 

The Department of Health and Human 

Service’s overall goal for the investment 

in comparative effectiveness research is 

to promote high quality care through 

broad availability of information that 

helps clinicians and patients match the 

best science to individual needs and 

preferences. Moreover, the investment 

can build a sustainable foundation for 

CER so that it will enable—now and in 

the future the United States healthcare 

system to deliver the highest quality and 

best value care to all Americans. 

Funding Opportunity 

Announcements soliciting grant 

applications and Requests for Contracts 

for CER will provide $210.5 million for 

data infrastructure and related research, 

$89.5 million for dissemination and 

translation, $71 million for research, 

$7.6 million for inventory and 

evaluation projects and $4 million for 

WReier-Aviles on DSKGBLS3C1PROD with NOTICES

Federal Register / Vol. 75, No. 4 / Thursday, January 7, 2010 / Notices 991 

salary and benefits for ARRA-related 

staff and administrative support. 

An additional, $17.4 million will be 

allocated to projects that address any 

gaps within the new and existing CER 

programs. 

Dated: December 30, 2009. 

Carolyn M. Clancy, 

AHRQ, Director. 

[FR Doc. E9–31340 Filed 1–6–10; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Notice of Meeting; National 

Commission on Children and Disasters 

AGENCY: Administration for Children 

and Families, Department of Health and 

Human Services. 

ACTION: Notice of Meeting. 

DATES: The meeting will be held on 

Monday, February 1, 2010, from 9 a.m. 

to 5:30 p.m. 

ADDRESSES: The meeting will be held at 

the Renaissance Mayflower Hotel, 1127 

Connecticut Avenue, NW., Washington, 

DC 20036. To attend in person, please 

register by 5 p.m. Eastern Time, January 

28, 2010. To register, please visit 

http:// 

www.childrenanddisasters.acf.hhs.gov. 

If you experience technical difficulties, 

please contact 

NCCDregister@theambitgroup.com. If 

you require a sign language interpreter 

or other special assistance, please call 

Jacqueline Haye at (202) 205–9560 or email jacqueline.haye@acf.hhs.gov as 

soon as possible and no later than 5 

p.m. Eastern Time, January 19, 2010. 

Agenda: The National Commission on 

Children and Disasters is hosting a 

Long-Term Disaster Recovery Workshop 

to explore challenges and solutions that 

impact the unique needs of children. 

This one day forum provides an 

opportunity for Federal, State, Tribal, 

local and non-governmental partners to 

inform the Commission as it prepares its 

Final Report to the President and the 

Congress, due October 2010. Key issues 

that will be discussed at the workshop 

include children’s access to medical 

care, the provision of mental health 

services to children, and barriers to 

information and data sharing. 

Additional Information: Contacts: 

Roberta Lavin, Office of Human Services 

Emergency Preparedness and Response, 

e-mail Roberta.lavin@acf.hhs.gov or 

(202) 401–9306. 

SUPPLEMENTARY INFORMATION: The 

National Commission on Children and 

Disasters is an independent Commission 

that shall conduct a comprehensive 

study to examine and assess the needs 

of children as they relate to preparation 

for, response to, and recovery from all 

hazards, building upon the evaluations 

of other entities and avoiding 

unnecessary duplication by reviewing 

the findings, conclusions, and 

recommendations of these entities. The 

Commission shall then submit a report 

to the President and the Congress on the 

Commission’s independent and specific 

findings, conclusions, and 

recommendations to address the needs 

of children as they relate to preparation 

for, response to, and recovery from all 

hazards, including major disasters and 

emergencies. 

Dated: December 28, 2009. 

David A. Hansell, 

Principal Deputy Assistant Secretary for 

Children and Families. 

[FR Doc. E9–31402 Filed 1–6–10; 8:45 am] 

BILLING CODE 4184–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the 

National Advisory Mental Health 

Council. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Mental Health Council. 

Date: February 11–12, 2010. 

Closed: February 11, 2010, 10 a.m. to 5 

p.m. 

Agenda: To review and evaluate grant 

applications and review the activities of the 

NIMH Intramural Research Programs. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Conference Room C/D/E, 

Rockville, MD 20852. 

Open: February 12, 2010, 8:30 a.m. to 12:30 

p.m. 

Agenda: Presentation of NIMH Director’s 

report and discussion on NIMH program and 

policy issues. 

Place: National Institutes of Health, 

Building 31, C Wing, 31 Center Drive, 6th 

Floor, Conference Room 6, Bethesda, MD 

20892 

Contact Person: Jane A. Steinberg, PhD, 

Director, Division of Extramural Activities, 

National Institute of Mental Health, NIH, 

Neuroscience Center, 6001 Executive Blvd., 

Room 6154, MSC 9609, Bethesda, MD 20892– 

9609, 301–443–5047. 

Any member of the public interested in 

presenting oral comments to the committee 

may notify the Contact Person listed on this 

notice at least 10 days in advance of the 

meeting. Interested individuals and 

representatives of organizations may submit 

a letter of intent, a brief description of the 

organization represented, and a short 

description of the oral presentation. Only one 

representative of an organization may be 

allowed to present oral comments and if 

accepted by the committee, presentations 

may be limited to five minutes. Both printed 

and electronic copies are requested for the 

record. In addition, any interested person 

may file written comments with the 

committee by forwarding their statement to 

the Contact Person listed on this notice. The 

statement should include the name, address, 

telephone number and when applicable, the 

business or professional affiliation of the 

interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

www.nimh.nih.gov/about/advisory-boardsand-groups/namhc/index.shtml where an 

agenda and any additional information for 

the meeting will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.242, Mental Health Research 

Grants; 93.281, Scientist Development 

Award, Scientist Development Award for 

Clinicians, and Research Scientist Award; 

93.282, Mental Health National Research 

Service Awards for Research Training, 

National Institutes of Health, HHS) 

WReier-Aviles on DSKGBLS3C1PROD with NOTICES